Metsera (NASDAQ:MTSR – Get Free Report) issued its quarterly earnings data on Wednesday. The company reported ($3.52) earnings per share for the quarter, Zacks reports.
Metsera Stock Down 3.0 %
Shares of Metsera stock opened at $29.16 on Wednesday. Metsera has a 12-month low of $23.08 and a 12-month high of $32.81.
Analyst Upgrades and Downgrades
Several analysts have commented on the stock. Evercore ISI started coverage on shares of Metsera in a research report on Tuesday, February 25th. They set an “outperform” rating for the company. Cantor Fitzgerald started coverage on shares of Metsera in a research note on Tuesday, February 25th. They issued an “overweight” rating for the company. Bank of America initiated coverage on Metsera in a research report on Tuesday, February 25th. They set a “buy” rating and a $38.00 price target on the stock. Finally, Guggenheim initiated coverage on Metsera in a research report on Tuesday, February 25th. They issued a “buy” rating and a $56.00 price objective for the company.
About Metsera
Metsera, Inc is a clinical stage biopharmaceutical company, which engages in the development of a next-generation injectable and oral nutrient stimulated hormone, or NuSH, analog peptides to treat obesity, overweight and related conditions. Its product pipeline includes MET-097i, MET-233, and MET-224o.
Read More
- Five stocks we like better than Metsera
- Dividend Payout Ratio Calculator
- Palantir Setting Up to Be a Big Winner With New Defense Spending
- How to Calculate Return on Investment (ROI)
- Advanced Micro Devices Can Double in Price: Here’s Why
- Stock Analyst Ratings and Canadian Analyst Ratings
- How Disney’s Experiences Segment Can Restore the House of Mouse
Receive News & Ratings for Metsera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Metsera and related companies with MarketBeat.com's FREE daily email newsletter.
